Susan G. Komen® Applauds Bill Introduction; Urges Quick Passage
Susan G. Komen®, the world’s leading breast cancer organization, commends Senator Brenda Stanley (R-Midwest City) and Representative Nicole Miller (R-Northwest Oklahoma City and West Edmond) for introducing legislation that would eliminate financial barriers to clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing.
Germline testing is a type of test that looks for inherited mutations that have been present in every cell of the body since birth. In the U.S., 5-10% of breast cancers are related to a known inherited gene mutation. The lifetime risk of breast cancer increases 20-49% for women with moderate risk inherited gene mutations and 50% or more for women with high-risk inherited gene mutations.
SB 109/HB 2270, introduced by Sen. Stanley and Rep. Miller, eliminates the patient out-of-pocket costs for multi-gene panel testing for inherited gene mutations and evidence-based screenings, ensuring individuals have access to critical information regarding their lifetime cancer risk and recommended early detection and cancer surveillance.
“This legislation ensures patients have a better understanding their lifetime cancer risk and access to needed risk reduction and treatment strategies,” said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen. “Understanding cancer risk shouldn’t depend on financial means. This legislation helps eliminates barriers, empowering individuals with essential knowledge to make informed decisions about their health.”
“Having walked the cancer journey with my husband and sister, I know firsthand how vital early detection is in the fight against this disease,” Stanley said. “Prevention and timely intervention saves lives. This legislation is a powerful step forward in ensuring that every Oklahoman has access to the critical genetic testing and screenings they may need. It is my hope to give families the tools they need to make informed decisions about their health and create a future where fewer lives are lost to breast cancer.”
Identification of inherited cancer risk can help guide decisions regarding recommended screenings for the early detection of cancer, personalized cancer treatments and risk-reducing medical treatments. Studies have shown an estimated 83% of eligible patients that underwent multigene panel testing had changes to their medical management, including modifications in follow-up and chemotherapy strategy.
“The fight against breast cancer is deeply personal for me, and I know firsthand the critical role early detection and preventative measures can play. By eliminating out-of-pocket costs for multi-gene panel testing and screenings, we empower Oklahomans with the knowledge and tools to make informed decisions about their health. This legislation isn’t just about access—it’s about saving lives and giving families hope,” said Miller, who is herself a breast cancer survivor.